Overcoming Resistance: Enhancing CDK4/6 Inhibitor Efficacy in Advanced Breast Cancer Treatment

Event Details
CDK4/6 inhibitors in combination with endocrine therapy is becoming the standard of care for first-line treatment of ER+/HER2-negative advanced breast cancer. Resistance to these agents has been extensively studied; however, whether acquired resistance mechanisms are dependent on the duration of clinical treatment before progression is unclear. During this webinar, participants will hear from our Chief Scientific Officer, Dr. Michael J. Wick, and learn: 1) Background and specifics on three FDA-approved CDK4/6 inhibitors. 2) Published and novel mechanisms of resistance identified in ER+ breast PDX models established from patients who progressed on CDK4/6 inhibitor treatment within the first year and beyond. 3) Potential for resensitizing resistant patients through combination therapy.

Date & Time:

July 9, 2024


Zoom Webinar

For more information visit: